ESR1 and cancer: When we looked at relapse-free survival at 5 years in an independent cohort using the ROC Plotter database [19], we observed that endocrine therapy, anti-HER therapy and chemotherapy were more efficient in ER, HER+ and TNBC cancers, respectively.